Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys

In the present study, age-associated effects of the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) administered via the right carotid artery were evaluated pre- and post-MPTP treatment in 26 female rhesus monkeys ranging in age from young adulthood to middle age (5 to 23 years old). A significant inverse correlation was seen between age and MPTP dose needed to produce stable, moderate parkinsonian features. Rhesus in the 5- to 9-year-old group required approximately three times the amount of MPTP as 20- to 23-year-old animals. Even though they received less MPTP, the older animals consistently displayed more severe bradykinesia, upper limb rigidity, and balance and gait abnormalities. Prior to MPTP treatment, home cage activity levels were strongly age dependent, with animals in the 10- to 19-year and 20- to 23-year groups displaying significantly less daytime activity than 5- to 9-year-old rhesus. Home cage activity levels tended to decrease in all age groups following MPTP treatment, but significant decreases were only measured in daytime activity in the 10- to 19- and 20- to 23-year age groups.

[1]  Z. Zhang,et al.  Developing a stable bilateral model of parkinsonism in rhesus monkeys , 1993, Neuroscience.

[2]  W. Nicklas,et al.  MPTP, MPP+ and mitochondrial function. , 1987, Life sciences.

[3]  P. Goldman-Rakic,et al.  Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys , 1981, Neuroscience.

[4]  B. A. Brooks,et al.  Behavioral and biochemical studies in monkeys made hemiparkinsonian by MPTP , 1987, Brain Research.

[5]  S. Walsh,et al.  Age‐dependent effects of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): Correlation with monoamine oxidase‐B , 1989, Synapse.

[6]  R. Kurlan,et al.  The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐tetrahydropyridine to monkeys , 1991, Annals of neurology.

[7]  J. Langston,et al.  The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment , 1992, Brain Research.

[8]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[9]  G. Gerhardt,et al.  In Vivo Electrochemical Measurements of Exogenous Dopamine Clearance in Normal and Neonatal 6-Hydroxydopamine-Treated Rat Striatum , 1993, Experimental Neurology.

[10]  P. Mcgeer,et al.  Aging and extrapyramidal function. , 1977, Archives of neurology.

[11]  D. Price,et al.  Amyloid precursor protein in aged nonhuman primates. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Price,et al.  Senile plaques in cortex of aged normal monkeys , 1985, Brain Research.

[13]  W. Nicklas,et al.  IV. MPTP, MPP+ and mitochondrial function , 1987 .

[14]  J. Langston,et al.  Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment , 1986, Brain Research.

[15]  R. Kurlan,et al.  Oral levodopa dose‐response study in MPTP‐induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism , 1991, Movement disorders : official journal of the Movement Disorder Society.

[16]  S J Kish,et al.  Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.

[17]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[18]  M. Moss.  The longitudinal assessment of recognition memory in aged rhesus monkeys , 1993, Neurobiology of Aging.

[19]  M. Herkenham,et al.  Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study , 1991, Neuroscience.

[20]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[21]  Greg A. Gerhardt,et al.  Age-related changes in potassium-evoked overflow of dopamine in the striatum of the rhesus monkey , 1995, Neurobiology of Aging.

[22]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[23]  W Slikker,et al.  MPTP‐induced oxidative stress and neurotoxicity are age‐dependent: Evidence from measures of reactive oxygen species and striatal dopamine levels , 1994, Synapse.

[24]  J. Kordower,et al.  NGF-like trophic support from peripheral nerve for grafted rhesus adrenal chromaffin cells. , 1990, Journal of neurosurgery.

[25]  B J Hoffer,et al.  Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum. , 1992, The Journal of pharmacology and experimental therapeutics.

[26]  C. Olanow.  A radical hypothesis for neurodegeneration , 1993, Trends in Neurosciences.

[27]  R. Kurlan,et al.  Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease , 1994, Annals of neurology.

[28]  D. Price,et al.  Age-related changes in multiple neurotransmitter systems in the monkey brain , 1989, Neurobiology of Aging.

[29]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[30]  K. Jellinger,et al.  Overview of morphological changes in Parkinson's disease. , 1987, Advances in neurology.

[31]  S. Markey.  MPTP, a neurotoxin producing a Parkinsonian syndrome , 1986 .

[32]  J. Tigges,et al.  Survival rate and life span of rhesus monkeys at the Yerkes regional primate research center , 1988, American journal of primatology.

[33]  M. Strolin Benedetti,et al.  Monoamine oxidase, brain ageing and degenerative diseases. , 1989, Biochemical pharmacology.

[34]  R. Bartus.  General overview: Past contributions and future opportunities using aged nonhuman primates , 1993, Neurobiology of Aging.

[35]  I. Date,et al.  Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis , 1990, Brain Research.

[36]  R. Roth,et al.  MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys , 1990, Brain Research.

[37]  D. Jacobowitz,et al.  Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.

[38]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[39]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Sparks,et al.  Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease. , 1991, Archives of neurology.

[41]  H. Uno.  The incidence of senile plaques and multiple infarction in aged Macaque brain , 1993, Neurobiology of Aging.

[42]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  H. Tohgi,et al.  [Aging and Parkinson's disease]. , 1991, No to shinkei = Brain and nerve.

[44]  G. Gerhardt,et al.  Increased dopamine clearance in the non-lesioned striatum of rhesus monkeys with unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) striatal lesions , 1995, Neuroscience Letters.

[45]  M. Voytko.  Cognitive changes during normal aging in monkeys assessed with an automated test apparatus , 1993, Neurobiology of Aging.

[46]  Markesbery Wr,et al.  Alterations in Brain Monoamine Oxidase Activity in Aging, Alzheimer's Disease, and Pick's Disease , 1991 .

[47]  M. Beal,et al.  Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1994, Brain Research.

[48]  Y. Agid,et al.  Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? , 1993, Neuroscience.